EUVIMEDEUVIMED entdecken
Crossref

Distinct Prognostic Roles of 18 F-FDG PET Metabolic Response Assessed After Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell Carcinoma

Yeong Hak Bang, Jong Hoon Kim, Yong-Hee Kim, Hyeong Ryul Kim, Jin-Sook Ryu, Yong-Il Kim, Joon Seon Song, Sung-Bae Kim, Sook Ryun Park

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.125.269775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Yeong Hak Bang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Chemoradiotherapy, Esophageal Squamous Cell Carcinoma, Induction Chemotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prognostic significance of metabolic response by posttreatment 18F-FDG PET in esophageal squamous cell carcinoma (ESCC) treated with chemoradiotherapy remains unclear, particularly regarding metabolic response after induction chemotherapy versus after chemoradiotherapy. This study aimed to evaluate and compare their prognostic impact.

Methods

This retrospective study analyzed 604 patients with localized ESCC who received induction chemotherapy followed by chemoradiotherapy, with or without surgery, at Asan Medical Center between 2006 and 2018. Metabolic responses after induction chemotherapy (before chemoradiotherapy) and after chemoradiotherapy were evaluated using European Organisation for Research and Treatment of Cancer-based criteria adapted for prognostic assessment.

Results

In patients treated with definitive chemoradiotherapy (bimodality therapy), metabolic response after both induction chemotherapy and chemoradiotherapy was significantly associated with progression-free survival (PFS) and overall survival (OS). Complete metabolic response after induction chemotherapy correlated with the longest survival (PFS, 58.9 mo; OS, 90.8 mo), whereas progressive metabolic disease predicted poor prognosis (PFS, 3.7 mo; OS, 7.0 mo; P < 0.001). A similar pattern was observed for postchemoradiotherapy metabolic response. In patients who underwent surgery (trimodality therapy), metabolic response after induction chemotherapy did not significantly impact survival. However, in patients for whom surgery was initially planned, it remained prognostic, suggesting its prognostic relevance in the preoperative setting. Postchemoradiotherapy metabolic response was a strong independent prognostic factor in both bimodality therapy and trimodal therapy. Patients with diffuse esophagitis after chemoradiotherapy had intermediate survival outcomes, among complete metabolic response and partial metabolic response groups, indicating a distinct prognostic pattern.

Conclusion

Postchemoradiotherapy metabolic response is a strong prognostic marker in localized ESCC, supporting its use for risk stratification. Early metabolic response after induction chemotherapy may also inform treatment decisions, particularly in surgery-intended patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18ChemoradiotherapyEsophageal Squamous Cell CarcinomaInduction ChemotherapyEsophageal NeoplasmsPositron-Emission TomographyHumansMaleFemaleMiddle AgedRetrospective StudiesPrognosisAgedAdultTreatment Outcome

Stichwörter der Autor:innen

18F-FDG PETchemoradiotherapyesophageal squamous cell carcinomainduction chemotherapymetabolic responseprognosis

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Thoracic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; and.
  • Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; srpark@amc.seoul.kr.

Zitieren

APA

Bang, Y. H., Kim, J. H., Kim, Y. H., Kim, H. R., Ryu, J. S., Kim, Y. I., Song, J. S., Kim, S. B., & Park, S. R. (2025). Distinct Prognostic Roles of 18 F-FDG PET Metabolic Response Assessed After Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell Carcinoma. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.269775

Vancouver

Bang YH, Kim JH, Kim YH, Kim HR, Ryu JS, Kim YI, et al. Distinct Prognostic Roles of 18 F-FDG PET Metabolic Response Assessed After Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell Carcinoma. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.269775

BibTeX
@article{Bang2025,
  author = {Bang, Yeong Hak and Kim, Jong Hoon and Kim, Yong-Hee and Kim, Hyeong Ryul and Ryu, Jin-Sook and Kim, Yong-Il and Song, Joon Seon and Kim, Sung-Bae and Park, Sook Ryun},
  title = {Distinct Prognostic Roles of 18 F-FDG PET Metabolic Response Assessed After Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell Carcinoma},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.125.269775}
}
Kostenlos starten →